4.7 Review

The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives

期刊

FEMS MICROBIOLOGY REVIEWS
卷 45, 期 3, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/femsre/fuaa060

关键词

Candida; Candida infections; antifungal immunity; microbiota; mycobiota; fungus-host-microbiota interactions; patient variability; fungal variability; microbiota variability

资金

  1. European Union [812969]
  2. French Government 'Investissement d'Avenir' program (Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases) [ANR-10-LABX-62-IBEID]
  3. Agence Nationale de la Recherche (ERA-Net Infect-ERA, FUNCOMPATH) [ANR-14-IFEC-0004]
  4. EU Horizon2020 consortium `Host-Directed Medicine in invasive FUNgal infections'-HDM-FUN [847507]
  5. National Science Foundation [CRSII5 173863]
  6. French Government 'Investissement d'Avenir' program [ANR-10-AIRT-03]
  7. Alexander von Humboldt-Foundation
  8. Deutsche Forschungsgemeinschaft (DFG) [434385622/GR 5617/1-1, Hu 532/20-1, 390713860]
  9. Leibniz Association Campus InfectoOptics [SAS-2015-HKILWC]
  10. Wellcome Trust [215599/Z/19/Z, 097377/Z/11/Z]
  11. Instituto de Salud Carlos III/FEDER
  12. ERC [833247]
  13. Netherlands Organization for Scientific Research
  14. Scottish Government's Rural and Environment Science and Analytical Services (RESAS)
  15. UK Medical Research Council [MR/M026663/1]
  16. Medical Research Council Centre for Medical Mycology at the University of Exeter [MR/N006364/1]
  17. EU Horizon2020 consortium `Host-DirectedMedicine in invasive FUNgal infections'-HDM-FUN [847507]
  18. Agence Nationale de la Recherche (ANR) [ANR-14-IFEC-0004] Funding Source: Agence Nationale de la Recherche (ANR)
  19. Swiss National Science Foundation (SNF) [CRSII5_173863] Funding Source: Swiss National Science Foundation (SNF)
  20. MRC [MR/N006364/2, MR/M026663/2, MR/N006364/1, MR/M026663/1] Funding Source: UKRI

向作者/读者索取更多资源

Candida albicans is a major fungal pathogen of humans that can lead to mucosal infections and life-threatening systemic infections. The interactions between fungus, host, and microbiota play a key role in disease development, and understanding these variables could lead to targeted antifungal therapies for vulnerable patients.
Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据